In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia.
Achondroplasia is a rare genetic disorder caused by mutations in the Fibroblast Growth Factor receptor 3 (FGFR3). These mutations lead to aberrant increase of inhibitory signaling in proliferating chondrocytes at the growth plate. Recifercept is a potential treatment for this disease using a decoy a...
Main Authors: | Diogo Gonçalves, Guylène Rignol, Pierre Dellugat, Guido Hartmann, Stephanie Sarrazy Garcia, Jeffrey Stavenhagen, Luca Santarelli, Elvire Gouze, Christian Czech |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0244368 |
Similar Items
-
Early postnatal soluble FGFR3 therapy prevents the atypical development of obesity in achondroplasia.
by: Celine Saint-Laurent, et al.
Published: (2018-01-01) -
Obesity in achondroplasia patients: from evidence to medical monitoring
by: Celine Saint-Laurent, et al.
Published: (2019-11-01) -
Natural history of 39 patients with Achondroplasia
by: Jose Ricardo Magliocco Ceroni, et al.
Published: (2018-07-01) -
Achondroplasia Associated with Bilateral Keratoconus
by: Ammar M. Al Mahmood, et al.
Published: (2012-01-01) -
The achondroplasia mutation rate paradox
by: Henderson, Shirley
Published: (2002)